Bristol Myers Squibb had a strong quarter, with key drugs old and new coming in either above or in line with Wall Street’s ...

Besides Wall Street's top-and-bottom-line estimates for Pfizer (PFE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

The biopharmaceutical industry is growing rapidly as a result of significant advancements in biotechnology and drug development. Due to developments in ...

On July 2, linvoseltamab-gcpt (Lynozyfic; Regeneron) received an accelerated approval from the FDA in relapsed/refractory ...

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

Emory’s Sagar Lonial, MD, a world-class leader in his specialty, harnesses teamwork to advance the treatment of multiple ...

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies find ...

One relatively safe bet about how Pfizer's lineup will look different five years from now is that the company will be a ...

On July 25, Leads Biolabs made its official debut on the Hong Kong Stock Exchange. Its shares surged as much as 117% intraday ...

Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, ...